Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients

Authors :: Adam A Anas
Casper Rokx
Marijn Smits-Zwinkels
Bart J. A. Rijnders
Robert-Jan Hassing
Susanne Bogers
C. Ellen van der Schoot
Carlijn C E Jordans
Ilse M.G. Hageman
Anne Marie de Man
Marjolein van der Klift
Maaike Meertens
Francis Swaneveld
Ella C van den Hout
Marc Blaauw
Corine H. GeurtsvanKessel
Arvind Gharbharan
Internal Medicine
Medical Microbiology & Infectious Diseases
Virology
Source :: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 74(7), 1271-1274. Oxford University Press
Publication Year :: 2021
Publisher :: Oxford University Press (OUP), 2021.
Abstract: Twenty-five B-cell–depleted patients (24 following anti-CD19/20 therapy) diagnosed with coronavirus disease 2019 had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent plasma with high neutralizing antibody titers. Twenty-one (84%) recovered, indicating the potential therapeutic effects of this therapy in this particular population.

Tools